;PMID: 8518837
;source_file_1944.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..153] = [t:44..153]
;2)section:[e:157..196] = [t:157..196]
;3)section:[e:200..278] = [t:200..278]
;4)sentence:[e:282..412] = [t:282..412]
;5)sentence:[e:413..621] = [t:413..621]
;6)sentence:[e:622..802] = [t:622..802]
;7)sentence:[e:803..1048] = [t:803..1048]
;8)sentence:[e:1049..1154] = [t:1049..1154]
;9)sentence:[e:1155..1345] = [t:1155..1345]
;10)sentence:[e:1346..1494] = [t:1346..1494]
;11)sentence:[e:1495..1685] = [t:1495..1685]
;12)sentence:[e:1686..1857] = [t:1686..1857]
;13)section:[e:1861..1905] = [t:1861..1905]

;section 0 Span:0..38
;Pharmacogenetics. 1993 Apr;3(2):77-85.
(SEC
  (FRAG (NNP:[0..16] Pharmacogenetics) (,:[16..17] .) (CD:[18..22] 1993)
        (CC:[23..29] Apr;3-LRB-) (CD:[29..30] 2) (-RRB-:[30..31] -RRB-)
        (CD:[31..34] :77) (::[34..35] -) (CD:[35..37] 85) (.:[37..38] .)))

;sentence 1 Span:44..153
;Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence
;for  rapid and slow metabolizers.
;[63..74]:substance:"tolbutamide"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[44..51] Hepatic) (JJ:[52..62] microsomal)
          (NN:[63..74] tolbutamide) (NN:[75..88] hydroxylation))
      (PP (IN:[89..91] in)
        (NP (JJ:[92..100] Japanese))))
    (::[100..101] :)
    (NP
      (NP
        (ADJP (FW:[102..104] in) (FW:[105..110] vitro))
        (NN:[111..119] evidence))
      (PP (IN:[120..123] for)
        (NP
          (NP (JJ:[125..130] rapid)
            (NML-1 (-NONE-:[130..130] *P*)))
          (CC:[131..134] and)
          (NP (JJ:[135..139] slow)
            (NML-1 (NNS:[140..152] metabolizers))))))
    (.:[152..153] .)))

;section 2 Span:157..196
;Chen LS, Yasumori T, Yamazoe Y, Kato R.
(SEC
  (FRAG (NNP:[157..161] Chen) (NNP:[162..164] LS) (,:[164..165] ,)
        (NNP:[166..174] Yasumori) (NNP:[175..176] T) (,:[176..177] ,)
        (NNP:[178..185] Yamazoe) (NNP:[186..187] Y) (,:[187..188] ,)
        (NNP:[189..193] Kato) (NNP:[194..196] R.)))

;section 3 Span:200..278
;Department of Pharmacology, School of Medicine, Keio University, Tokyo,
;Japan.
(SEC
  (FRAG (NNP:[200..210] Department) (IN:[211..213] of)
        (NNP:[214..226] Pharmacology) (,:[226..227] ,) (NNP:[228..234] School)
        (IN:[235..237] of) (NNP:[238..246] Medicine) (,:[246..247] ,)
        (NNP:[248..252] Keio) (NNP:[253..263] University) (,:[263..264] ,)
        (NNP:[265..270] Tokyo) (,:[270..271] ,) (NNP:[272..277] Japan)
        (.:[277..278] .)))

;sentence 4 Span:282..412
;Microsomal hydroxylation of tolbutamide in Japanese livers was studied in
;vitro  to ascertain the enzyme catalysing this reaction.
;[310..321]:substance:"tolbutamide"
;[380..386]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[282..292] Microsomal) (NN:[293..306] hydroxylation))
      (PP (IN:[307..309] of)
        (NP (NN:[310..321] tolbutamide)))
      (PP-LOC (IN:[322..324] in)
        (NP (JJ:[325..333] Japanese) (NNS:[334..340] livers))))
    (VP (VBD:[341..344] was)
      (VP (VBN:[345..352] studied)
        (NP-1 (-NONE-:[352..352] *))
        (ADVP (FW:[353..355] in) (FW:[356..361] vitro))
        (S-PRP
          (NP-SBJ (-NONE-:[361..361] *))
          (VP (TO:[363..365] to)
            (VP (VB:[366..375] ascertain)
              (NP
                (NP (DT:[376..379] the) (NN:[380..386] enzyme))
                (VP (VBG:[387..397] catalysing)
                  (NP (DT:[398..402] this) (NN:[403..411] reaction)))))))))
    (.:[411..412] .)))

;sentence 5 Span:413..621
;Rates of tolbutamide  hydroxylation differed individually 33-fold and 42-fold
;at 0.1 mM and 2.4 mM  tolbutamide concentrations, respectively, and were
;segregated into two groups,  rapid and slow metabolizers.
;[422..433]:substance:"tolbutamide"
;[471..478]:quantitative-value:"33-fold"
;[483..490]:quantitative-value:"42-fold"
;[494..497]:quantitative-value:"0.1"
;[498..500]:quantitative-units:"mM"
;[505..508]:quantitative-value:"2.4"
;[509..511]:quantitative-units:"mM"
;[513..524]:substance:"tolbutamide"
(SENT
  (S
    (NP-SBJ-4
      (NP (NNS:[413..418] Rates))
      (PP (IN:[419..421] of)
        (NP (NN:[422..433] tolbutamide) (NN:[435..448] hydroxylation))))
    (VP
      (VP (VBD:[449..457] differed)
        (ADVP (RB:[458..470] individually))
        (ADVP-EXT
          (ADVP
            (QP (CD:[471..473] 33) (HYPH:[473..474] -) (RB:[474..478] fold)))
          (CC:[479..482] and)
          (ADVP
            (QP (CD:[483..485] 42) (HYPH:[485..486] -) (RB:[486..490] fold))))
        (PP (IN:[491..493] at)
          (NP
            (NP
              (NML
                (NML (CD:[494..497] 0.1) (NN:[498..500] mM))
                (NML-2 (-NONE-:[500..500] *P*)))
              (NML-3 (-NONE-:[500..500] *P*)))
            (CC:[501..504] and)
            (NP
              (NML
                (NML (CD:[505..508] 2.4) (NN:[509..511] mM))
                (NML-2 (NN:[513..524] tolbutamide)))
              (NML-3 (NNS:[525..539] concentrations)))))
        (,:[539..540] ,)
        (ADVP (RB:[541..553] respectively)))
      (,:[553..554] ,) (CC:[555..558] and)
      (VP (VBD:[559..563] were)
        (VP (VBN:[564..574] segregated)
          (NP-4 (-NONE-:[574..574] *))
          (PP (IN:[575..579] into)
            (NP
              (NP (CD:[580..583] two) (NNS:[584..590] groups))
              (,:[590..591] ,)
              (NP
                (NP (JJ:[593..598] rapid)
                  (NML-1 (-NONE-:[598..598] *P*)))
                (CC:[599..602] and)
                (NP (JJ:[603..607] slow)
                  (NML-1 (NNS:[608..620] metabolizers)))))))))
    (.:[620..621] .)))

;sentence 6 Span:622..802
;An antibody raised against P450 human-2 (a form of  CYP2C9) strongly
;inhibited the hydroxylation in livers of rapid metabolizers but  only weakly
;inhibited in the slow metabolizer.
;[625..633]:substance:"antibody"
;[649..661]:cyp450:"P450 human-2"
;[674..680]:cyp450:"CYP2C9"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[622..624] An) (NN:[625..633] antibody))
      (VP (VBN:[634..640] raised)
        (NP (-NONE-:[640..640] *))
        (PP (IN:[641..648] against)
          (NP
             (NN:[649..653] P450) (NN:[654..661] human-2)
            (PRN (-LRB-:[662..663] -LRB-)
              (NP
                (NP (DT:[663..664] a) (NN:[665..669] form))
                (PP (IN:[670..672] of)
                  (NP (NN:[674..680] CYP2C9))))
              (-RRB-:[680..681] -RRB-))))))
    (VP
      (VP
        (ADVP (RB:[682..690] strongly))
        (VBD:[691..700] inhibited)
        (NP
          (NP (DT:[701..704] the) (NN:[705..718] hydroxylation))
          (PP-1 (-NONE-:[718..718] *ICH*)))
        (PP-LOC (IN:[719..721] in)
          (NP (NNS:[722..728] livers)))
        (PP-1 (IN:[729..731] of)
          (NP (JJ:[732..737] rapid) (NNS:[738..750] metabolizers))))
      (CC:[751..754] but)
      (VP
        (ADVP (RB:[756..760] only))
        (ADVP (RB:[761..767] weakly))
        (VBD:[768..777] inhibited)
        (PP (IN:[778..780] in)
          (NP (DT:[781..784] the) (JJ:[785..789] slow)
              (NN:[790..801] metabolizer)))))
    (.:[801..802] .)))

;sentence 7 Span:803..1048
;Kinetic experiments further  demonstrated a clear distinction in tolbutamide
;hydroxylation between two  groups; the mean of apparent Km values for
;tolbutamide was 0.25 mM (n = 3) in  the rapid group and 2.58 mM (n = 2) in
;the slow, respectively.
;[868..879]:substance:"tolbutamide"
;[936..938]:quantitative-name:"Km"
;[950..961]:substance:"tolbutamide"
;[966..970]:quantitative-value:"0.25"
;[971..973]:quantitative-units:"mM"
;[1006..1010]:quantitative-value:"2.58"
;[1011..1013]:quantitative-units:"mM"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[803..810] Kinetic) (NNS:[811..822] experiments))
      (ADVP (RB:[823..830] further))
      (VP (VBD:[832..844] demonstrated)
        (NP
          (NP (DT:[845..846] a) (JJ:[847..852] clear)
              (NN:[853..864] distinction))
          (PP (IN:[865..867] in)
            (NP (NN:[868..879] tolbutamide) (NN:[880..893] hydroxylation)))
          (PP (IN:[894..901] between)
            (NP (CD:[902..905] two) (NNS:[907..913] groups))))))
    (::[913..914] ;)
    (S
      (NP-SBJ
        (NP (DT:[915..918] the) (NN:[919..923] mean))
        (PP (IN:[924..926] of)
          (NP
            (NP (JJ:[927..935] apparent) (NN:[936..938] Km)
                (NNS:[939..945] values))
            (PP (IN:[946..949] for)
              (NP (NN:[950..961] tolbutamide))))))
      (VP
        (VP (VBD:[962..965] was)
          (NP-PRD=1 (CD:[966..970] 0.25) (NN:[971..973] mM)
            (PRN (-LRB-:[974..975] -LRB-)
              (S
                (NP-SBJ (NN:[975..976] n))
                (VP (SYM:[977..978] =)
                  (NP (CD:[979..980] 3))))
              (-RRB-:[980..981] -RRB-)))
          (PP=2 (IN:[982..984] in)
            (NP (DT:[986..989] the) (JJ:[990..995] rapid) (NN:[996..1001] group))))
        (CC:[1002..1005] and)
        (VP
          (NP-PRD=1 (CD:[1006..1010] 2.58) (NN:[1011..1013] mM)
            (PRN (-LRB-:[1014..1015] -LRB-)
              (S
                (NP-SBJ (NN:[1015..1016] n))
                (VP (SYM:[1017..1018] =)
                  (NP (CD:[1019..1020] 2))))
              (-RRB-:[1020..1021] -RRB-)))
          (PP=2 (IN:[1022..1024] in)
            (NP (DT:[1025..1028] the) (JJ:[1029..1033] slow))))
        (,:[1033..1034] ,)
        (ADVP (RB:[1035..1047] respectively))))
    (.:[1047..1048] .)))

;sentence 8 Span:1049..1154
;These data  suggest that different enzymes are involved in the hydroxylation
;in both  metabolizer groups.
;[1084..1091]:substance:"enzymes"
(SENT
  (S
    (NP-SBJ (DT:[1049..1054] These) (NNS:[1055..1059] data))
    (VP (VBP:[1061..1068] suggest)
      (SBAR (IN:[1069..1073] that)
        (S
          (NP-SBJ-1 (JJ:[1074..1083] different) (NNS:[1084..1091] enzymes))
          (VP (VBP:[1092..1095] are)
            (VP (VBN:[1096..1104] involved)
              (NP-1 (-NONE-:[1104..1104] *))
              (PP-CLR (IN:[1105..1107] in)
                (NP
                  (NP (DT:[1108..1111] the) (NN:[1112..1125] hydroxylation))
                  (PP (IN:[1126..1128] in)
                    (NP (DT:[1129..1133] both) (NN:[1135..1146] metabolizer)
                        (NNS:[1147..1153] groups))))))))))
    (.:[1153..1154] .)))

;sentence 9 Span:1155..1345
;Furthermore, CYP2C9 produced by cDNA expression in yeasts,  catalysed
;tolbutamide hydroxylation at rates similar to the rapid metabolizer  group at
;both the 0.1 mM and 2.4 mM concentrations.
;[1168..1174]:cyp450:"CYP2C9"
;[1187..1191]:substance:"cDNA"
;[1225..1236]:substance:"tolbutamide"
;[1312..1315]:quantitative-value:"0.1"
;[1316..1318]:quantitative-units:"mM"
;[1323..1326]:quantitative-value:"2.4"
;[1327..1329]:quantitative-units:"mM"
(SENT
  (S
    (ADVP (RB:[1155..1166] Furthermore))
    (,:[1166..1167] ,)
    (NP-SBJ
      (NP (NN:[1168..1174] CYP2C9))
      (VP (VBN:[1175..1183] produced)
        (NP (-NONE-:[1183..1183] *))
        (PP (IN:[1184..1186] by)
          (NP-LGS (NN:[1187..1191] cDNA) (NN:[1192..1202] expression)))
        (PP-LOC (IN:[1203..1205] in)
          (NP (NNS:[1206..1212] yeasts)))))
    (,:[1212..1213] ,)
    (VP (VBD:[1215..1224] catalysed)
      (NP (NN:[1225..1236] tolbutamide) (NN:[1237..1250] hydroxylation))
      (PP (IN:[1251..1253] at)
        (NP
          (NP (NNS:[1254..1259] rates))
          (ADJP (JJ:[1260..1267] similar)
            (PP (TO:[1268..1270] to)
              (NP (DT:[1271..1274] the) (JJ:[1275..1280] rapid)
                  (NN:[1281..1292] metabolizer) (NN:[1294..1299] group))))
          (PP (IN:[1300..1302] at)
            (NP (CC:[1303..1307] both) (DT:[1308..1311] the)
              (NML
                (NML
                  (NML (CD:[1312..1315] 0.1) (NN:[1316..1318] mM))
                  (NML-1 (-NONE-:[1318..1318] *P*)))
                (CC:[1319..1322] and)
                (NML
                  (NML (CD:[1323..1326] 2.4) (NN:[1327..1329] mM))
                  (NML-1 (NNS:[1330..1344] concentrations)))))))))
    (.:[1344..1345] .)))

;sentence 10 Span:1346..1494
;The apparent Km value of the  expressed protein for tolbutamide, 0.26 mM, was
;similar to that determined for  the rapid group of microsomal samples.
;[1359..1361]:quantitative-name:"Km"
;[1386..1393]:substance:"protein"
;[1398..1409]:substance:"tolbutamide"
;[1411..1415]:quantitative-value:"0.26"
;[1416..1418]:quantitative-units:"mM"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1346..1349] The) (JJ:[1350..1358] apparent)
            (NN:[1359..1361] Km) (NN:[1362..1367] value))
        (PP (IN:[1368..1370] of)
          (NP (DT:[1371..1374] the) (VBN:[1376..1385] expressed)
              (NN:[1386..1393] protein)))
        (PP (IN:[1394..1397] for)
          (NP (NN:[1398..1409] tolbutamide))))
      (,:[1409..1410] ,)
      (NP (CD:[1411..1415] 0.26) (NN:[1416..1418] mM)))
    (,:[1418..1419] ,)
    (VP (VBD:[1420..1423] was)
      (ADJP-PRD (JJ:[1424..1431] similar)
        (PP (TO:[1432..1434] to)
          (NP
            (NP (DT:[1435..1439] that))
            (VP (VBN:[1440..1450] determined)
              (NP (-NONE-:[1450..1450] *))
              (PP (IN:[1451..1454] for)
                (NP
                  (NP (DT:[1456..1459] the) (JJ:[1460..1465] rapid)
                      (NN:[1466..1471] group))
                  (PP (IN:[1472..1474] of)
                    (NP (JJ:[1475..1485] microsomal) (NNS:[1486..1493] samples))))))))))
    (.:[1493..1494] .)))

;sentence 11 Span:1495..1685
;Clear correlations were observed between  the rate of microsomal tolbutamide
;hydroxylation at 0.1 mM and CYP2C9 protein  content or the rate of
;S-mephenytoin 4'-hydroxylation in human liver.
;[1560..1571]:substance:"tolbutamide"
;[1589..1592]:quantitative-value:"0.1"
;[1593..1595]:quantitative-units:"mM"
;[1600..1614]:cyp450:"CYP2C9 protein"
;[1639..1652]:substance:"S-mephenytoin"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1495..1500] Clear) (NNS:[1501..1513] correlations))
    (VP (VBD:[1514..1518] were)
      (VP (VBN:[1519..1527] observed)
        (NP-1 (-NONE-:[1527..1527] *))
        (PP (IN:[1528..1535] between)
          (NP
            (NP
              (NP (DT:[1537..1540] the) (NN:[1541..1545] rate))
              (PP (IN:[1546..1548] of)
                (NP (JJ:[1549..1559] microsomal) (NN:[1560..1571] tolbutamide)
                    (NN:[1572..1585] hydroxylation)))
              (PP (IN:[1586..1588] at)
                (NP (CD:[1589..1592] 0.1) (NN:[1593..1595] mM))))
            (CC:[1596..1599] and)
            (NP
              (NP
                (NP
                   (NN:[1600..1606] CYP2C9) (NN:[1607..1614] protein)
                  (NN:[1616..1623] content))
                (CC:[1624..1626] or)
                (NP
                  (NP (DT:[1627..1630] the) (NN:[1631..1635] rate))
                  (PP (IN:[1636..1638] of)
                    (NP (NN:[1639..1652] S-mephenytoin)
                        (NN:[1653..1669] 4'-hydroxylation)))))
              (PP (IN:[1670..1672] in)
                (NP (JJ:[1673..1678] human) (NN:[1679..1684] liver))))))))
    (.:[1684..1685] .)))

;sentence 12 Span:1686..1857
;These  results indicate that considerable portions of microsomal tolbutamide 
;hydroxylation are catalysed by CYP2C9 or the closely related form in the
;rapid  metabolizers.
;[1751..1762]:substance:"tolbutamide"
;[1795..1801]:cyp450:"CYP2C9"
(SENT
  (S
    (NP-SBJ (DT:[1686..1691] These) (NNS:[1693..1700] results))
    (VP (VBP:[1701..1709] indicate)
      (SBAR (IN:[1710..1714] that)
        (S
          (NP-SBJ-1
            (NP (JJ:[1715..1727] considerable) (NNS:[1728..1736] portions))
            (PP (IN:[1737..1739] of)
              (NP (JJ:[1740..1750] microsomal) (NN:[1751..1762] tolbutamide)
                  (NN:[1764..1777] hydroxylation))))
          (VP (VBP:[1778..1781] are)
            (VP (VBN:[1782..1791] catalysed)
              (NP-1 (-NONE-:[1791..1791] *))
              (PP (IN:[1792..1794] by)
                (NP-LGS
                  (NP (NN:[1795..1801] CYP2C9))
                  (CC:[1802..1804] or)
                  (NP (DT:[1805..1808] the)
                    (ADJP (RB:[1809..1816] closely) (VBN:[1817..1824] related))
                    (NN:[1825..1829] form))))
              (PP (IN:[1830..1832] in)
                (NP (DT:[1833..1836] the) (JJ:[1837..1842] rapid)
                    (NNS:[1844..1856] metabolizers))))))))
    (.:[1856..1857] .)))

;section 13 Span:1861..1905
;PMID: 8518837 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1861..1865] PMID) (::[1865..1866] :) (CD:[1867..1874] 8518837)
        (NN:[1875..1876] -LSB-) (NNP:[1876..1882] PubMed) (::[1883..1884] -)
        (NN:[1885..1892] indexed) (IN:[1893..1896] for)
        (NNP:[1897..1905] MEDLINE-RSB-)))
